Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the National Cancer Data Base

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 5, 2015, Pages 1052-1063

  Amini, Arya ^a   Jones, Bernard L ^a   Yeh, Norman ^a   Rusthoven, Chad G ^a   Armstrong, Hirotatsu ^a   Kavanagh, Brian D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; MULTIVARIANT ANALYSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; HIGH-RISK PATIENTS; HIGH-RISK PROSTATE CANCERS; METHODS AND MATERIALS; MULTIVARIATE ANALYSIS; PROGNOSTIC FACTORS; PROSTATE SPECIFIC ANTIGEN; RECURSIVE PARTITIONING ANALYSIS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE ONLY RADIATION THERAPY; RADIATION DOSE ESCALATION; SURVIVAL; VERY ELDERLY; WHOLE PELVIC RADIATION THERAPY; BLOOD; CANCER GRADING; EPIDEMIOLOGY; FACTUAL DATABASE; INSURANCE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PELVIS; PROCEDURES; PROPENSITY SCORE; PROSTATE; PROSTATIC NEOPLASMS; RADIATION DOSE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DATABASES, FACTUAL; HUMANS; INSURANCE COVERAGE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PELVIS; PROPENSITY SCORE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84946780258     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.09.006     Document Type: Article

References (32)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
2. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
3. D.A. Kuban, S.L. Tucker, L. Dong, and et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
4. A.L. Zietman, M.L. DeSilvio, J.D. Slater, and et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
5. J. Michalski, J. Moughan, J. Purdy, and et al. A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer J Clin Oncol 33 2015 (suppl 7; abstr 4)
6. R.K. Valicenti, K. Bae, J. Michalski, and et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06 Int J Radiat Oncol Biol Phys 79 2011 1323 1329
7. S.O. Asbell, J.M. Krall, M.V. Pilepich, and et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316
8. S.O. Asbell, K.L. Martz, K.H. Shin, and et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06: A phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma Int J Radiat Oncol Biol Phys 40 1998 769 782
9. M. Roach 3rd, M. DeSilvio, C. Lawton, and et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
10. C.A. Lawton, M. DeSilvio, M. Roach 3rd, and et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
11. P. Pommier, S. Chabaud, J.L. Lagrange, and et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
12. RTOG 0924 Protocol Information. Available at: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0924. Accessed July 2015.
13. American College of Surgeons: National Cancer Data Base. Available at: https://www.facs.org/quality%20programs/cancer/ncdb. Accessed July 2015.
14. National Comprehensive Cancer Network (NCCN). Available at: http://www.nccn.org. Accessed July 2015.
15. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
16. M. Roach III, C. Marquez, H.S. Yuo, and et al. Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1994 33 37
17. Coca-Perraillon M. Local and global optimal propensity score matching. In SAS Global Forum 2007;1-9.
18. A. Ciampi, S.A. Hogg, S. McKinney, and et al. A computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. I. Methods and program features Comput Methods Programs Biomed 26 1988 239 256
19. G. Mantini, L. Tagliaferri, G.C. Mattiucci, and et al. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy Int J Radiat Oncol Biol Phys 81 2011 e721 e726
20. S.A. Seaward, V. Weinberg, P. Lewis, and et al. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation Cancer J Sci Am 4 1998 370 377
21. M.T. Spiotto, S.L. Hancock, and C.R. King Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients Int J Radiat Oncol Biol Phys 69 2007 54 61
22. A.A. Aizer, J.B. Yu, A.M. McKeon, and et al. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma Int J Radiat Oncol Biol Phys 75 2009 1344 1349
23. C.C. Pan, K.Y. Kim, J.M. Taylor, and et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy Int J Radiat Oncol Biol Phys 53 2002 1139 1145
24. L.F. Da Pozzo, C. Cozzarini, A. Briganti, and et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: The positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
25. P. Milecki, M. Baczyk, J. Skowronek, and et al. Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer J Biomed Biotechnol 2009 2009 625394
26. C.E. Vargas, R. Galalae, J. Demanes, and et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation Int J Radiat Oncol Biol Phys 63 2005 1474 1482
27. C.E. Vargas, J. Demanes, T.P. Boike, and et al. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy Am J Clin Oncol 29 2006 451 457
28. D.E. Soto, S. Glaser, R.H. Roberts, and et al. Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer Urology 71 2008 313 317
29. R. Jacob, A.L. Hanlon, E.M. Horwitz, and et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement Int J Radiat Oncol Biol Phys 61 2005 695 701
30. K. Fizazi, L. Faivre, F. Lesaunier, and et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial Lancet Oncol 16 2015 787 794
31. P.F. Blanchard, L. Faivre, F. Lesaunier, and et al. Outcomes according to elective pelvic radiotherapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 phase III randomized trial Int J Radiat Oncol Biol Phys 2015 In Press
32. A phase III of cabazitaxel and pelvic radiotherapy in localized prostate cancer and high-risk features of relapse (PEACE2). Available at: https://clinicaltrials.gov/ct2/show/NCT01952223. Accessed July 2015.